ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Association of chemotherapy with survival in stage II colon cancer patients who received radical surgery: a retrospective cohort study

Lv, Zhihao*; Liang, Yuqi; Liu, Huaxi; Mo, Delong广州中医药大学; 南方医科大学
BMC CANCER2021-3-23DOI: 10.1186/s12885-021-08057-3
10被引11阅读
引用收藏
分享

摘要

BackgroundIt remains controversial whether patients with Stage II colon cancer would benefit from chemotherapy after radical surgery. This study aims to assess the real effectiveness of chemotherapy in patients with stage II colon cancer undergoing radical surgery and to construct survival prediction models to predict the survival benefits of chemotherapy.MethodsData for stage II colon cancer patients with radical surgery were retrieved from the Surveillance, Epidemiology, and End Results (SEER) database. Propensity score matching (1:1) was performed according to receive or not receive chemotherapy. Competitive risk regression models were used to assess colon cancer cause-specific death (CSD) and non-colon cancer cause-specific death (NCSD). Survival prediction nomograms were constructed to predict overall survival (OS) and colon cancer cause-specific survival (CSS). The predictive abilities of the constructed models were evaluated by the concordance indexes (C-indexes) and calibration curves.ResultsA total of 25,110 patients were identified, 21.7% received chemotherapy, and 78.3% were without chemotherapy. A total of 10,916 patients were extracted after propensity score matching. The estimated 3-year overall survival rates of chemotherapy were 0.7% higher than non- chemotherapy. The estimated 5-year and 10-year overall survival rates of non-chemotherapy were 1.3 and 2.1% higher than chemotherapy, respectively. Survival prediction models showed good discrimination (the C-indexes between 0.582 and 0.757) and excellent calibration.ConclusionsChemotherapy improves the short-term (43months) survival benefit of stage II colon cancer patients who received radical surgery. Survival prediction models can be used to predict OS and CSS of patients receiving chemotherapy as well as OS and CSS of patients not receiving chemotherapy and to make individualized treatment recommendations for stage II colon cancer patients who received radical surgery.

学科与关键词

关键词
Colon cancerSEERChemotherapyNomogramCompeting-risk model
相关
加载中…
  • Real-world survival of colon cancer after radical surgery: A single-institutional retrospective analysis
    Pang, Xiangyi; Xu, Benjie; Lian, Jie; Wang, Ren; Wang, Xin; Shao, Jiayue; Tang, Shuli; Lu, Haibo*Frontiers in Oncology, 2022, 12: 914076.被引 4
  • Adjuvant chemotherapy benefits on patients with elevated carcinoembryonic antigen in stage IIA colon cancer: a SEER-based analysis
    Zhou, Huabin; Wang, Songsheng; Cai, Zhai; Qiu, Enming; Chen, Qianyun; Rao, Xi; Han, Shuai; Li, Zhou*INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2022, 37(12): 2481-2489.
  • Prognostic value of final pathological stage in colon adenocarcinoma after neoadjuvant chemotherapy: A propensity score-matched study
    Xiang, Meijuan; Liang, Zongyu; Gao, Yuan; Feng, Xingyu*; Yao, Xueqing*Frontiers in Surgery, 2022, 9: 1022025.被引 1
查看全部 →

发表信息

论文状态
公开发表
期刊
BMC CANCER
发表日期
2021-03-23
卷期
第 21 卷, 第 1 期
页码
306
DOI
10.1186/s12885-021-08057-3
语言
ENGLISH
期刊收录
NSL
期刊等级
2区
成果收录
SCIE

作者

  • L

    Lv, Zhihao (通讯) (第一作者)

    guangzhou univ chinese med

  • L

    Liang, Yuqi

    guangzhou univ chinese med

查看全部 4 位作者收起作者
  • L

    Liu, Huaxi

    southern med univ

  • M

    Mo, Delong

    guangzhou univ chinese med

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417